3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
4
Myelodysplastic Syndromes
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Interventions
Cyclophosphamide
42
Cytarabine
25
fludarabine phosphate
24
Dexamethasone
23
Methotrexate
22
fludarabine
21
Peripheral Blood Stem Cell Transplantation
21
Vincristine
16
Filgrastim
16
venetoclax
14
Etoposide
13
Rituximab
12
Mycophenolic Acid
12
Whole-Body Irradiation
11
Cyclosporine
10
Clofarabine
10
Calcium Dobesilate
10
blinatumomab
9
Tacrolimus
9
pegaspargase
8
Busulfan
8
Bortezomib
8
Alemtuzumab
8
Mitoxantrone
7
Melphalan
7
Leucovorin
7
Immunotherapy, Adoptive
7
nilotinib
6
Mesna
6
Mercaptopurine
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
posaconazole
×
Clear all
NCT07155226
2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2
Recruiting
84 enrolled